title: Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes.
abstract: Statins increase bone morphogenetic protein-2 (BMP-2) mRNA expression and subsequently increase new bone formation in vitro. However, the action of statins on the BMP-2 mRNA regulation of cartilage matrix synthesis by chondrocytes is unknown. We evaluated regulation of BMP-2, aggrecan, and type II collagen (COL2) mRNA and (35)S-labeled proteoglycan (PG) synthesis by mevastatin using cultured chondrocytes obtained from articular cartilage of fetal rats. Expression of BMP-2, aggrecan, and COL2 mRNAs were increased in the presence of 2 microM mevastatin on day 2. However, longer (10 day) culture in the presence of the drug decreased the expression of these mRNAs. PG synthesis was increased 3 days after treating the cells with mevastatin, which was also decreased with longer (10 day) mevastatin treatment. These results suggest that mevastatin increases mRNA expression of BMP-2, aggrecan, and COL2 as well as PG synthesis by fetal rat chondrocytes early in the treatment period. We suggest that statins have implications for fracture and cartilage repair.
authors.affiliation: Department of Orthopedic Research, Mayo Clinic and Foundation, MSB 3-69, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hatano
authors.forename: Akihiro
authors.initials: A
authors.lastname: Maruo
authors.forename: Mark E
authors.initials: ME
authors.lastname: Bolander
authors.forename: Gobinda
authors.initials: G
authors.lastname: Sarkar
mesh_terms: D053674:Aggrecans; D000704:Analysis of Variance; D000818:Animals; D001483:Base Sequence; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000187:drug effects* / Q000235:genetics; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects / Q000502:physiology; D024043:Collagen Type II / Q000187:drug effects* / Q000235:genetics; D016326:Extracellular Matrix Proteins; D005260:Female; D005786:Gene Expression Regulation; D037181:Lectins, C-Type; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008297:Male; D008969:Molecular Sequence Data; D011336:Probability; D011509:Proteoglycans / Q000096:biosynthesis* / Q000187:drug effects* / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012680:Sensitivity and Specificity; D016212:Transforming Growth Factor beta
chemical_list: C508321:Acan protein, rat; D053674:Aggrecans; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D024043:Collagen Type II; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; C012258:mevastatin; D008148:Lovastatin